Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.23.5 (
cathepsin D
)
4,130
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A novel estrogen receptor (ER)alpha coactivator complex, the
MLL2
complex, which consists of
MLL2
, ASH2, RBQ3, and WDR5, was identified. ERalpha directly binds to the
MLL2
complex through two LXXLL motifs in a region of
MLL2
near the C terminus in a ligand-dependent manner. Disrupting the interaction between ERalpha and the
MLL2
complex with small interfering RNAs specific against
MLL2
or an
MLL2
fragment representing the interacting region with ERalpha significantly inhibited the ERalpha transcription activity. The
MLL2
complex was recruited on promoters of ERalpha target genes along with ERalpha upon estrogen stimulation. Inhibition of
MLL2
expression decreased the estrogen-induced expression of ERalpha target genes
cathepsin D
and to a lesser extent pS2. In addition, MCF-7 cell growth was also inhibited by the depletion of
MLL2
. These results demonstrate that the ERalpha signaling pathway is critically dependent on its direct interaction with the
MLL2
complex and suggest a central role for the
MLL2
complex in the growth of ERalpha-positive cancer cells.
...
PMID:Identification of the MLL2 complex as a coactivator for estrogen receptor alpha. 1660 32
